Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension
Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension
复制标题
DOI：
10.1002/lt.500050517
复制
发表时间：
1999-09-01
期刊：
影响因子：
--
通讯作者：
Porayko, MK
中科院分区：
文献类型：
--
作者：
Findlay, JY;Plevak, DJ;Porayko, MK
患有终末期肝衰竭、门静脉高压和相关肺动脉高压（门脉肺动脉高压[PPHTN]）的患者在接受肝移植时死亡率很高。这些患者的成功移植可能取决于降低肺动脉压 (PAP) 的努力。为此，许多中心正在使用依前列醇连续静脉 (IV) 输注，这已被证明可以改善原发性肺动脉高压患者的症状、延长寿命并降低 PAP。我们报告了 4 例 PPHTN 患者接受连续静脉注射依前列醇治疗后出现进行性脾肿大、血小板减少和白细胞减少恶化的情况。这一发现可能会限制依前列醇在 PPHTN 中的用途，并影响此类患者的移植时机，美国肝病研究协会版权所有 (C) 1999。
Patients with end-stage liver failure, portal hypertension, and associated pulmonary artery hypertension (portopulmonary hypertension [PPHTN]) have a high mortality when undergoing liver transplantation. Successful transplantation in these patients may depend on efforts to reduce pulmonary artery pressure (PAP), To this end, a number of centers are using a continuous intravenous (IV) infusion of epoprostenol, which has been shown to improve symptoms, extend life span, and reduce PAP in patients with primary pulmonary hypertension. We report four cases in which treatment of patients with PPHTN with continuous IV epoprostenol was followed by the development of progressive splenomegaly, with worsening thrombocytopenia and leukopenia. This finding may limit the usefulness of epoprostenol in PPHTN and influence the timing of transplantation in such patients, Copyright (C) 1999 by the American Association for the Study of Liver Diseases.